B+
Bull case
30%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
BVS
BioventusBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Pain Treatments growth, conversion of deferred Ultrasonics orders, and a value-accretive strategic outcome could lift the shares. Bioventus reaffirmed 2026 net-sales guidance of $600 million–$610 million, adjusted EPS of $0.75–$0.79, and operating cash flow of $84 million–$89 million.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.7.
What can break
No timetable or assurance of a transaction from the strategic-alternatives review. [#SEC-8K-2026-08-05]
Momentum
86
Value
63
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $18.00 · Bear $9.50Analysis 2026-10-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-10 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $17.60
Why
Momentum86 · Δ7d +8.8
Value63 · Δ7d -0.7
Sentiment47 · Δ7d -15.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.7.
Contradictions & invalidation
- • No timetable or assurance of a transaction from the strategic-alternatives review. [#SEC-8K-2026-08-05]
- • Q2 GAAP earnings benefited from a $24.6 million deferred-tax-asset valuation-allowance release. [#SEC-8K-2026-08-05]
- • The strategic review may end without a transaction.
Catalyst clock
2026-12-31
Strategic-alternatives review
Lead driver: Value · See fundamentals
Momentum
86
8% active weight
Current posture
7d trendFlat
Δ7d
+8.8
Δ21d
-4.2
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-0.6
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
-15.3
Δ21d
-20.5
Why this grade
Composite grade B. Momentum 85.8 / Value 62.7 / Sentiment 46.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-10. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$1.24B
Beta
0.79
Shares Out
68.31M
P/E (TTM)
67.4
P/S (TTM)
1.11
P/FCF (TTM)
11.72
Rev YoY
+3.8%
EPS YoY
+333.9%
Gross Margin
+67.8%
Op Margin
+10.6%
Net Debt
$260.11M
Current Ratio
1.69
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data